Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study

被引:71
作者
Mathiesen, P. [1 ]
Hegaard, H. [2 ]
Herlin, T. [3 ]
Zak, M. [4 ]
Pedersen, F. K. [4 ]
Nielsen, S. [4 ]
机构
[1] Copenhagen Univ Hosp Holbaek, Dept Paediat, DK-4300 Holbaek, Denmark
[2] Copenhagen Univ Hosp, JMC Panum, Res Sect 3341, Rigshosp, Copenhagen, Denmark
[3] Aarhus Univ Hosp Skejby, Paediat Rheumatol Dept, Aarhus, Denmark
[4] Copenhagen Univ Hosp, Paediat Rheumatol Unit, Rigshosp, Copenhagen, Denmark
关键词
NATIONAL-INSTITUTE; PROGNOSTIC-FACTORS; CLINICAL-FEATURES; CORE SET; VALIDATION; CHILDREN; ADULT; QUESTIONNAIRE; POLYMYOSITIS; RELIABILITY;
D O I
10.3109/03009742.2011.608376
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate a group of 53 patients with juvenile dermatomyositis (JDM), on average 13.9 years after disease onset, in order to describe the long-term disease outcome and to identify disease-related parameters associated with poor disease outcome. Methods: Baseline information at disease onset was obtained from medical records. Disease status at follow-up was evaluated by physical examination. The Myositis Damage Index (MDI) and the Myositis Disease Damage by Visual Analogue Scale (MYODAM-VAS) were used to describe disease damage. Results: Disease damage was seen in 60.4% of patients. The most common damage was cutaneous scarring (39.6%) and muscle dysfunction (34%). Calcinosis was found in 20%, lipodystrophy in 13%, and severe damage affecting more than two organ systems in 24.5% of patients. A disease duration > 4 years increased the risk of damage based on: MDI score [adjusted odds ratio (AOR) 8.3, 95% confidence interval (CI) 1.7-41.7], MYODAM-VAS score (AOR 26.2, 95% CI 3.1-223.7), and number of affected organs (AOR 16.3, 95% CI 1.1-232.4). Disease onset age >= 7.4 years increased the risk of more than two affected organs (AOR 15.8, 95% CI 1.9-129.4). Disease duration >= 4 years increased the risk of calcinosis (OR 4.8, 95% CI 1.1-20.9) and continuous muscle dysfunction (OR 4.2, 95% CI 1.1-17.3). Conclusion: In a long-term follow-up study, 60% of JDM patients had disease damage at a mean of 14 years after disease onset. Longer disease duration was the most important predictor of damage, calcinosis, and impaired muscle function, and higher age at disease onset predicted more organs involved at follow-up.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 34 条
  • [1] Alexanderson H, 2002, J RHEUMATOL, V29, P2386
  • [2] Disease activity score for children with juvenile dermatomyositis: Reliability and validity evidence
    Bode, RK
    Klein-Gitelman, MS
    Miller, ML
    Lechman, TS
    Pachman, LM
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (01): : 7 - 15
  • [3] POLYMYOSITIS AND DERMATOMYOSITIS .2.
    BOHAN, A
    PETER, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) : 403 - 407
  • [4] POLYMYOSITIS AND DERMATOMYOSITIS .1.
    BOHAN, A
    PETER, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) : 344 - 347
  • [5] Cassidy JT, 2010, TXB PEDIAT RHEUMATOL, P375
  • [6] Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood
    Feldman, Brian M.
    Rider, Lisa G.
    Reed, Ann M.
    Pachman, Lauren M.
    [J]. LANCET, 2008, 371 (9631) : 2201 - 2212
  • [7] Aggressive management of Juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis
    Fisler, RE
    Liang, MG
    Fuhlbrigge, RC
    Yalcindag, A
    Sundel, RP
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (04) : 505 - 511
  • [8] Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?
    Huber A.
    Feldman B.M.
    [J]. Current Rheumatology Reports, 2005, 7 (6) : 441 - 446
  • [9] Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies
    Huber, AM
    Feldman, BM
    Rennebohm, RM
    Hicks, JE
    Lindsley, CB
    Perez, MD
    Zemel, LS
    Wallace, CA
    Ballinger, SH
    Passo, MH
    Reed, AM
    Summers, RM
    White, PH
    Katona, IM
    Miller, FW
    Lachenbruch, PA
    Rider, LG
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (05): : 1595 - 1603
  • [10] Huber AM, 2000, ARTHRITIS RHEUM, V43, P541, DOI 10.1002/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO